1. Scrip
  2. >>Focus On Asia
  3. >>China

INTERVIEW: Ally Bridge CEO On De-Risking China And Investing In 2016

 
• By Jules Quartly

With $1bn under management, the Hong Kong private equity firm Ally Bridge Group bagged multiple deals in 2015 including WuXi's $3.3bn privatization. CEO Frank Yu spoke to PharmAsia News about pursuing a holistic approach that goes beyond its China roots.

HONG KONG – Foreign investment in Asia’s life science companies is commonplace, but investment groups operating outside the region are often viewed as being less sophisticated or liable to put their money into areas where others fear to tread.

One company seeking to reverse this preconception is Ally Bridge Group (ABG), a pioneer of the “value added cross-border investment strategy.” The Hong Kong-based private equity firm has a growing reputation for disruptive technology platform funding in medical devices and biopharmaceuticals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs